Sanofi ‘considering’ raising Genzyme offer

January 19, 2011
Manufacturing and Production, Research and Development, Sales and Marketing Genzyme, Sanofi, Sanofi-Aventis, pharma mergers and acquisitions

Sanofi-Aventis could be willing to raise its offer to $76 a share to buy the US biotech firm Genzyme, according …

Success in pre-clinical microRNA treatment of prostate cancer

January 19, 2011
Research and Development MD Anderson Cancer Center, MicroRNA, Mirna Therapeutics, RNA interfering, miRNA, prostate cancer, rnai

A new MicroRNA treatment for prostate cancer has been highly effective against the disease in pre-clinical studies. MicroRNAs, or miRNAs, …

Syntaxin appoints Russell Greig chairman

January 19, 2011
Research and Development Russell Greig, appointment, research and development, syntaxin

Oxford, UK-based biotechnology company Syntaxin has appointed Dr Russell Greig as its new chairman.Russell has over 30 years experience in …

Online physician communities in UK and France join forces

January 19, 2011
Medical Communications, Sales and Marketing Egora, Global Media Sante, doctors communities, doctors.net, online communities

Two online communities for doctors have launched a strategic alliance to help them expand their reach. UK-based Doctors.net.uk is teaming …

Double Helix appoints Hollie Durrance and Gavin Harper

January 18, 2011
Medical Communications Double Helix, Gavin Harper, Hollie Durrance, appointment, medical communications

Global market research consultancy Double Helix has appointed Hollie Durrance as research manager and Gavin Harper as trainee research executive …

MPs hit out at NHS reforms

January 18, 2011
GP consortia, Health Select Committee, NHS, NHS reforms, PCTs

MPs have come out against the NHS White Paper, saying it has caused wide spread uncertainty at a time when …

European Commission launches new generic deal review

January 18, 2011
Sales and Marketing European Commission, anti-trust investigation, competition, generics

The European Commission has asked a number of firms to submit copies of their patent settlements in 2010 to see …

GSK takes £2.2bn hit from Avandia claims

January 18, 2011
Sales and Marketing Avandia, GSK, GlaxoSmithKline, rosiglitazone

GlaxoSmithKline’s Avandia woes are continuing, with the company admitting it expects to take a mammoth legal charge over the troubled …

Merck Serono and Domain to co-develop Parkinson’s drugs

January 18, 2011
Research and Development Domain Therapeutics, Merck KGaA, Merck Serono, PAM, Parkinson's disease, Parkinson’s disease, Positive Allosteric Modulator, mGluR4, metabotropic glutamate receptor 4

Merck Serono is to work with French biotech company Domain Therapeutics to develop a new treatment for Parkinson’s disease and …

Merck suffers late-stage blow to vorapaxar

January 18, 2011
Research and Development ACS, Merck & Co, acute coronary syndrome, anticoagulant, heart attack, peripheral arterial disease, stroke, vorapaxar

An increased risk of bleeding caused by pipeline drug vorapaxar has dealt Merck a major blow.The Data and Safety Monitoring …

BMS and Sanofi recall 64 million Avalide tablets

January 18, 2011
Manufacturing and Production Avalide, Avapro, Bristol-Myers Squibb, GMP, Good Manufacturing Practice, Sanofi-Aventis, hypertension, irbesartan

Bristol-Myers Squibb and Sanofi-Aventis have started another massive recall of their antihypertensive product Avalide because a manufacturing defect could affect …

Merck taps Parexel to help it meet biosimilar ambitions

January 18, 2011
Research and Development Merck & Co, Parexel, biosimilars

Merck & Co has enlisted the aid of contract research organisation Parexel to help it develop biosimilar versions of some …

Top doctors believe PCTs should stay

January 17, 2011
BMA, NHS, NHS reforms, PCTs, Royal College of GP

Leading GPs have criticised the government’s wide-ranging NHS reforms, saying minor structural changes are all the health service needs. A …

Sanofi-Aventis' Multaq (dronedarone)

FDA issues Multaq liver warning

January 17, 2011
Sales and Marketing FDA, Multaq, atrial fibrilation, dronedarone

US regulators have warned doctors and patients about the risk of severe liver injury associated with Sanofi-Aventis’ atrial fibrillation (AF) …

Blog footer

Digital Pharma: Sanofi launches diabetes blog

January 17, 2011
Medical Communications, Sales and Marketing Digital Pharma blog, Sanofi-Aventis, blog, diabetes

Sanofi-Aventis has ramped up its social media efforts with the launch of a blog about diabetes for US consumers. The …

Shire says new plant will add to Replagal, Vpriv capacity

January 17, 2011
Manufacturing and Production Cerezyme, Replagal, Shire, Vpriv

UK drugmaker Shire has completed construction of a new manufacturing facility for its orphan disease drugs Replagal and Vpriv, and …

Roche finance chief steps down

January 17, 2011
Sales and Marketing Alan Hippe, Erich Hunziker, Roche, appointment, sales and marketing

Roche’s chief financial officer Erich Hunziker is to retire at the end of March after ten years with the company. …

Novo Nordisk's Victoza

Diabetes drugs show promise in Alzheimer’s

January 17, 2011
Research and Development Alzheimer's, Alzheimer’s, Byetta, Novo Nordisk, Victoza, diabetes, exenatide, lilly, liraglutide

Research suggests that new diabetes drugs enhance cell growth in the brain, and could help treat Alzheimer’s disease. Researchers at …

Blog footer

Digital Pharma: NHS thrombosis e-learning

January 14, 2011
Medical Communications Bayer, Boehringer Ingelheim, Digital Pharma blog, NHS training, Pfizer, Sanofi-Aventis, VTE, e-learning, venous thromboembolism

The NHS has launched a best-practice website to help educate healthcare professionals about one of the most common causes of …

The Gateway to Local Adoption Series

Latest content